Compare
Silexion Therapeutics Corp vs VivoSim Labs, Inc. vs Exozymes Inc. vs AIM ImmunoTech Inc.
| Latest fiscal year | Silexion Therapeutics Corp SLXN | VivoSim Labs, Inc. VIVS | Exozymes Inc. EXOZ | AIM ImmunoTech Inc. AIM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $131.0K | n/a | $88.0K |
| Revenue growth (YoY) | n/a | -9.0% | n/a | -48.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/m |
| Net margin | n/a | n/m | n/a | n/m |
| Net income | -$11.91M | -$13.84M | -$9.16M | -$13.96M |
| EPS (Diluted) | $8.96 | -$5.35 | -$1.09 | -$8.62 |
| Operating cash flow | -$10.82M | -$10.83M | -$6.50M | -$10.96M |
| Free cash flow | -$10.83M | -$10.83M | -$6.67M | n/a |
| Cash & equivalents | $5.99M | $5.02M | $3.04M | $2.98M |
| Total assets | $7.21M | $7.39M | $5.97M | $5.78M |
| Total liabilities | $4.61M | $8.48M | $2.57M | $15.56M |
| Shareholders' equity | $2.60M | -$1.10M | $3.40M | -$9.78M |
| Return on year-end equity | -457.6% | n/a | -269.6% | n/a |
| Shares outstanding | n/a | 2.89M | 8.41M | 3.07M |
Revenue, most recent five fiscal years
| Fiscal year | Silexion Therapeutics Corp | VivoSim Labs, Inc. | Exozymes Inc. | AIM ImmunoTech Inc. |
|---|---|---|---|---|
| Latest | n/a | $131.0K Ended 2026-03-31 | $70.1K Ended 2023-12-31 | $88.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $144.0K Ended 2025-03-31 | n/a | $170.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $109.0K Ended 2024-03-31 | n/a | $202.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $370.0K Ended 2023-03-31 | n/a | $141.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $1.50M Ended 2022-03-31 | n/a | $135.0K Ended 2021-12-31 |